# V2X, Inc.: overview

VVX · NYSE · CIK 1601548 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/vvx.md) · [Financials](/companies/vvx/financials.md) · [Filings](/companies/vvx/filings.md) · [Insiders](/companies/vvx/insiders.md)

Latest reported revenue: [$1.26bn](/filings/0001601548-26-000038.md) for Q2 FY2026, three months to 2026-07-03, from the 10-Q filed Aug 3, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001601548-26-000038).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-27) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-28) | Q2 FY2025 (2025-06-27) | Q3 FY2025 (2025-09-26) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-04-03) | Q2 FY2026 (2026-07-03) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,082](/filings/0001601548-25-000066.md) | [1,158 d](/filings/0001601548-26-000015.md) | [1,016](/filings/0001601548-26-000025.md) | [1,078](/filings/0001601548-26-000038.md) | [1,167](/filings/0001601548-25-000066.md) | [1,219 d](/filings/0001601548-26-000015.md) | [1,254](/filings/0001601548-26-000025.md) | [1,257](/filings/0001601548-26-000038.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [4.6%](/filings/0001601548-25-000066.md) | [4.5% d](/filings/0001601548-26-000015.md) | [3.4%](/filings/0001601548-26-000025.md) | [4.9%](/filings/0001601548-26-000038.md) | [4.8%](/filings/0001601548-25-000066.md) | [4.2% d](/filings/0001601548-26-000015.md) | [3.5%](/filings/0001601548-26-000025.md) | [4.3%](/filings/0001601548-26-000038.md) |
| Net margin | % | [1.4%](/filings/0001601548-25-000066.md) | [2.2% d](/filings/0001601548-26-000015.md) | [0.8%](/filings/0001601548-26-000038.md) | [2.1%](/filings/0001601548-26-000038.md) | [2.1%](/filings/0001601548-25-000066.md) | [1.9% d](/filings/0001601548-26-000015.md) | [1.5%](/filings/0001601548-26-000038.md) | [2.0%](/filings/0001601548-26-000038.md) |
| Diluted EPS | $ per share | [0.47](/filings/0001601548-25-000066.md) | not reported | [0.25](/filings/0001601548-26-000025.md) | [0.70](/filings/0001601548-26-000038.md) | [0.77](/filings/0001601548-25-000066.md) | not reported | [0.60](/filings/0001601548-26-000025.md) | [0.81](/filings/0001601548-26-000038.md) |
| Free cash flow | $m | [60.5 d](/filings/0001601548-25-000066.md) | [222 d](/filings/0001601548-26-000015.md) | [(98.2)](/filings/0001601548-26-000025.md) | [26.1 d](/filings/0001601548-26-000038.md) | [35.0 d](/filings/0001601548-25-000066.md) | [207 d](/filings/0001601548-26-000015.md) | [(132)](/filings/0001601548-26-000025.md) | [20.5 d](/filings/0001601548-26-000038.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,784](/filings/0001601548-24-000004.md) | [2,891](/filings/0001601548-25-000009.md) | [3,963](/filings/0001601548-26-000015.md) | [4,322](/filings/0001601548-26-000015.md) | [4,480](/filings/0001601548-26-000015.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [3.5%](/filings/0001601548-24-000004.md) | [1.9%](/filings/0001601548-25-000009.md) | [3.1%](/filings/0001601548-26-000015.md) | [3.7%](/filings/0001601548-26-000015.md) | [4.3%](/filings/0001601548-26-000015.md) |
| Net margin | % | [2.6%](/filings/0001601548-24-000004.md) | [(0.5%)](/filings/0001601548-25-000009.md) | [(0.6%)](/filings/0001601548-26-000015.md) | [0.8%](/filings/0001601548-26-000015.md) | [1.7%](/filings/0001601548-26-000015.md) |
| Diluted EPS | $ per share | [3.86](/filings/0001601548-24-000004.md) | [(0.68)](/filings/0001601548-25-000009.md) | [(0.73)](/filings/0001601548-26-000015.md) | [1.08](/filings/0001601548-26-000015.md) | [2.45](/filings/0001601548-26-000015.md) |
| Free cash flow | $m | [51.6](/filings/0001601548-24-000004.md) | [81.1](/filings/0001601548-25-000009.md) | [163](/filings/0001601548-26-000015.md) | [242](/filings/0001601548-26-000015.md) | [170](/filings/0001601548-26-000015.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/vvx/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $329.1m | 4,414,201 |  | Added +671,935 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $189.7m | 2,544,621 |  | Added +16,015 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $130.6m | 1,752,272 |  | Reduced −5,617 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $119.5m | 1,602,609 |  | Added +98,902 |
| [REINHART PARTNERS, LLC.](/funds/1080298.md) | 2026-06-30 | $104.9m | 1,406,416 |  | Reduced −34,543 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $94.0m | 1,261,123 |  | Added +7,423 |
| [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $87.5m | 1,174,122 |  | Added +656,753 |
| [Ophir Asset Management Pty Ltd](/funds/1844640.md) | 2026-06-30 | $64.5m | 865,160 |  | Added +17,978 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $60.6m | 813,043 |  | Added +529,456 |
| [VICTORY CAPITAL MANAGEMENT INC](/funds/1040188.md) | 2026-06-30 | $57.3m | 768,616 |  | Reduced −55,139 |

## Recent filings

[All 919 filings](/companies/vvx/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-10 | 16:35 ET | [8-K](/filings/0001628280-26-055284.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001628280-26-055284 |
| 2026-08-03 | 16:07 ET | [8-K](/filings/0001601548-26-000039.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001601548-26-000039 |
| 2026-08-03 | 16:05 ET | [10-Q](/filings/0001601548-26-000038.md) | Quarterly report, period 2026-07-03 | 0001601548-26-000038 |
| 2026-06-01 | 16:10 ET | [8-K](/filings/0001628280-26-039479.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001628280-26-039479 |
| 2026-05-13 | 16:01 ET | [SCHEDULE 13D/A](/filings/0001193125-26-221556.md) | Ownership report, active investor, amended | 0001193125-26-221556 |
| 2026-05-11 | 16:05 ET | [8-K](/filings/0001104659-26-058637.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-058637 |
| 2026-05-07 | 16:02 ET | [8-K](/filings/0001104659-26-057088.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0001104659-26-057088 |
| 2026-05-04 | 16:07 ET | [8-K](/filings/0001601548-26-000026.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001601548-26-000026 |
| 2026-05-04 | 16:06 ET | [10-Q](/filings/0001601548-26-000025.md) | Quarterly report, period 2026-04-03 | 0001601548-26-000025 |
| 2026-03-19 | 07:50 ET | [DEF 14A](/filings/0001104659-26-031740.md) | Proxy statement, period 2026-05-07 | 0001104659-26-031740 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001601548-26-000015.md), filed Feb 23, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1601548
- Tickers: VVX
- Exchange: NYSE
- SIC code: 8744 Services-Facilities Support Management Services
- State of incorporation: IN
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 12:42 ET. No prices; not investment advice.